Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase NA 1

Status

Completed 6Recruiting 5Active not recruiting 5Not yet recruiting 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Gastrointestinal 3Other solid neoplasm 2Tumor-Agnostic 1

Conditions

Solid Tumors 2Stomach Neoplasms 1Neoplasms 1CLDN18.2-positive Gastric Adenocarcinoma 1CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction 1Adenocarcinoma 1

Interventions

Cyclophosphamide 1492Cisplatin 1414Paclitaxel 1317Radiotherapy 1261Carboplatin 1250Gemcitabine 1215Docetaxel 1109Bevacizumab 1030Fluorouracil 894Doxorubicin 792Dexamethasone 748Rituximab 719Capecitabine 716Oxaliplatin 700pembrolizumab 680Etoposide 678Irinotecan 634Filgrastim 621Cytarabine 586Leucovorin 579Nivolumab 558Vincristine 515Prednisone 475Cetuximab 465Bortezomib 459Erlotinib Hydrochloride 456Trastuzumab 447Methotrexate 438Lenalidomide 427Pemetrexed 420

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Completed × Interventional × zolbetuximab × Clear all
NCT01630083 2025-06-15

FAST

Astellas Pharma Inc

Phase 2 Completed
252 enrolled
Gastrointestinal

CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction

NCT01197885 2025-06-13

Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer

Astellas Pharma Inc

Phase 2 Completed
54 enrolled
Other solid neoplasm

Solid Tumors

NCT03528629 2024-12-02

A Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Astellas Pharma Inc

Phase NA Completed
18 enrolled
Gastrointestinal

Neoplasms, Stomach Neoplasms

NCT00909025 2024-11-21

Safety and Tolerability Study of Claudiximab in Patients With Advanced Gastroesophageal Cancer

Astellas Pharma Inc

Phase 1 Completed
15 enrolled
Other solid neoplasm

Solid Tumors

NCT04086758 2024-11-20

A Pharmacokinetic Study of Zolbetuximab (IMAB362) in Chinese Subjects With Locally Advanced Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma

Astellas Pharma Inc

Phase 1 Completed
12 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT01671774 2024-11-14

PILOT

Astellas Pharma Inc

Phase 1 Completed
29 enrolled
Gastrointestinal

CLDN18.2-positive Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡